Q32 Bio Inc.
QTTB Healthcare Biotechnology
Q32 Bio Inc.’s revenue for fiscal 2025 (year ended December 2025) was $53.7 million. In the quarter to June 2026, EPS grew 43.6%, free cash flow grew 71.1% and total debt fell 35.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow QTTB
Q32 Bio Inc. (QTTB) EV/Sales
As of 16 October 2026, Q32 Bio Inc. (QTTB) trades at a EV/Sales of −8.3×. Over the past ten years it has ranged from −80.4× (October 2024) to 400× (March 2020); the current reading is higher than 27% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −0.3× | — |
| FY2023 | −3.3× | — |
| FY2022 | −23.9× | — |
| FY2021 | 2.0× | (98.26%) |
| FY2020 | 117× | (67.99%) |
| FY2019 | 366× | 359.49% |
| FY2018 | 79.7× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2023 | −3.3× | — |
| Sep 2023 | −7.7× | — |
| Jun 2023 | −12.0× | — |
| Mar 2023 | −21.4× | — |
| 20 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| QTTB Q32 Bio Inc. | −8.3× |
| KROS Keros Therapeutics, Inc. compare | −1.4× |
| GLSI Greenwich LifeSciences, Inc. compare | n/m |
| LXEO Lexeo Therapeutics, Inc. compare | n/m |
| BBOT BridgeBio Oncology Therapeutics, Inc compare | n/m |
| FATE Fate Therapeutics, Inc. compare | 13.1× |
| SABS SAB Biotherapeutics, Inc. compare | 62.8× |
| SLGL Sol-Gel Technologies Ltd. compare | 127× |
| IMRX Immuneering Corporation compare | 260× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)